Skip to main content
OpenTrials
Not Yet Recruiting

NCT Number: NCT06079255

Ischemia Detection During Development of Acute Compartment Syndrome

This is an open, observational, prospective, descriptive, single-centre study including 60 patients. The study is designed to investigate if IscAlert sensor system can be used for reliable and continuous tissue carbon dioxide (pCO2)- and temperature monitoring in muscular tissue in lower extremity in patients at risk of developing acute compartment syndrome.

Not Yet Recruiting

Trial opening soon.

Get Notified

Key information

Age range

18 year–110 year

Sex eligibility

All sexes

Study type

Observational

Primary location

Oslo University Hospital

Oslo, 0424, Norway

Location contact

Monica Jensen, MD

SUB_INVESTIGATOR

Rolf B. Riise, MD

CONTACT

[email protected]

23076044 ext. +47

Sarmad Shafiq, MD

SUB_INVESTIGATOR

About this study

This is an open, observational, prospective, descriptive, single-centre study including 60 patients. The study is designed to investigate if IscAlert sensor system can be used for reliable and continuous tissue carbon dioxide (pCO2)- and temperature monitoring in muscular tissue in lower extremity in patients at risk of developing acute compartment syndrome.

The study will provide information regarding the clinical usefulness of tissue perfusion assessment by pCO2 and temperature monitoring in the diagnosis of patients at risk of developing acute compartment syndrome. Additionally, it will provide information regarding limits of pCO2 and temperature in the tissue indicating the need for fasciotomy. A fasciotomy will be performed independent of the measured pCO2 and temperature measurements in the muscle if clinical signs indicate a development of possible acute compartment syndrome. Measures of pain, and number of infections and bleeding caused by (or assumed to be caused by IscAlert) at insertion site will be registered.

The duration of investigation: In a patient: From insertion of first IscAlert™ sensor(s) to discharge from hospital. The sensors will usually be implanted for two days each. Follow up until 30 days after discharge from the hospital. 13 months of inclusion of all patients. There will be one last follow-up visit 1 year after discharge which will only look at sequelae after acute compartment syndrome and not sensors related issues.

Primary Aim: To assess if pCO2-levels when assessed with IscAlert correctly indicate the presence of acute compartment syndrome in muscular tissue in lower extremity in patients at risk of developing acute compartment syndrome.

Hypotheses

  • The pCO2 measurements will be at least 3 kPa higher when assessed with IscAlert in the muscle compartment where acute compartment syndrome develops compared to compartments where acute compartment syndrome does not develop.
  • No clinically significant pain, bleeding or infection will occur due to using IscAlert.
  • The temperature measurements will be lower when assessed with IscAlert in the muscle compartment where acute compartment syndrome develops compared to compartments where acute compartment syndrome does not develop.

Who can participate

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Must have a leg fracture that, perceived by the clinician, could give rise to later developing acute compartment syndrome condition.
  • Subject must be 18 years or more.
  • Able to sign informed consent.
  • Expected cooperation of the patients for the treatment and follow up

Exclusion criteria

  • Another study interfering with current study
  • Any reason why, in the opinion of the investigator, the patient should not participate.
  • Patients where a fasciotomy has already been decided should be performed

Treatment and study plan

IscAlert sensor(s) in patient with risk of acute compartment syndrome

Device

of the replanted extremity Insertion of a CO2- and temperature sensor(s) (IscAlert) in the anterior compartment of a lower limb (leg)

Primary outcomes

  1. Tissue CO2-level

    Time frame: 10 days

    Tissue CO2-level (kPa) during insertion period

Secondary outcomes

  1. Bleeding

    Time frame: 10 days

    Amount of blood from insertion site (ml)

  2. Infection

    Time frame: 30 days

    Infection from insertion site at the discretion of the investigator (yes or no)

  3. Pain at sensor insertion site

    Time frame: 30 days

    Pain at the insertion site measured by Numeric Rating Scale (0= no pain, 10= maximum pain)

  4. Pain in the lower leg during hospitalisation

    Time frame: 10 days

    Pain in the injured lower leg measured by Numeric Rating Scale (0= no pain, 10= maximum pain)

  5. Color of the lower leg

    Time frame: 10 days

    Skin color of the injured lower leg (Blue/Pink/Pale/Normal) during hospitalisation

  6. Paresthesia of the lower leg

    Time frame: 10 days

    Paresthesia of the injured lower leg (Yes/No) during hospitalisation

  7. Paralysis of the lower leg

    Time frame: 10 days

    Paralysis of the injured lower leg (Yes/No) during hospitalisation

  8. Lenght of sensor implantation time

    Time frame: 10 days

    Lenght of sensor implantation time during hospitalisation

  9. Time to discovery of reduced blood flow in lower leg

    Time frame: 10 days

    Number of days and hours from primary surgery end to obstructed blood flow is diagnosed.

  10. Number of re-operations

    Time frame: 30 days

    Number of reoperations (fasciotomies) caused by acute compartment syndrome

  11. Number of skin grafts performed

    Time frame: 1 year

    Number of skin grafts performed caused by sequelae after acute compartment syndrome

  12. Number of limb amputations performed

    Time frame: 1 year

    Number of limb amputations performed caused by sequelae after acute compartment syndrome

  13. Number of sensory deficit conditions

    Time frame: 1 year

    Number of sensory deficit conditions caused by sequelae after acute compartment syndrome

  14. Number of paralysis conditions

    Time frame: 1 year

    Number of paralysis conditions caused by sequelae after acute compartment syndrome

  15. Number of rhabdomyolysis conditions

    Time frame: 1 year

    Number of rhabdomyolysis conditions caused by sequelae after acute compartment syndrome

  16. Number of limb muscle contractures

    Time frame: 1 year

    Number of limb muscle contractures caused by sequelae after acute compartment syndrome

  17. Number of acute compartment syndrome conditions during hospitalisation

    Time frame: 30 days

    Number of acute compartment syndrome conditions during hospitalisation

  18. Number of acute compartment syndrome conditions after 1 year

    Time frame: 1 year

    Number of acute compartment syndrome conditions after 1 year

  19. Incidence of death 1 year

    Time frame: 1 year

    Mortality 1 year after admission

  20. Incidence of death during hospitalisation

    Time frame: 30 days

    Mortality during primary hospitalisation

  21. Lenght of stay during primary hospitalisation

    Time frame: 30 days

    Lenght of stay during primary hospitalisation

  22. Number of pack-years

    Time frame: 30 days

    Smoking habit; number of pack-years by participants

  23. Intravenous fluid

    Time frame: 12 hours

    Intravenous fluid given during surgery (ml)

  24. Vasoactive drugs

    Time frame: 12 hours

    Vasoactive drugs given during surgery (microgram)

  25. Tissue temperature level

    Time frame: 10 days

    Tissue temperature level (grade Celcius) during insertion period

  26. IscAlert functionality

    Time frame: 10 days

    Number of hours with a well-functioning sensor (giving CO2- and temperature data)

  27. Intracompartmental pressure

    Time frame: 10 days

    Intracompartmental pressure (mmHg) measured in anterior compartment of the injured leg

  28. Systolic blood pressure during hospitalisation

    Time frame: 10 days

    Systolic blood pressure (mmHg) during hospitalisation

  29. Diastolic blood pressure during hospitalisation

    Time frame: 10 days

    Diastolic blood pressure (mmHg) during hospitalisation

  30. Peripheral pulse during hospitalisation

    Time frame: 10 days

    Peripheral distal pulse (rate/minute) at the injured leg during hospitalisation

  31. Hemoglobin

    Time frame: 10 days

    Hemoglobin (g/dL) level during hospitalisation

  32. Creatine kinase

    Time frame: 10 days

    Creatine kinase (U/L) level during hospitalisation

Study contacts

Contact information is provided by the study sponsor or research team.

John Clarke-Jenssen, MD, PhD.

CONTACT

[email protected]

23027447 ext. +47

Tor Inge Tønnessen, MD, Ph.D.

CONTACT

[email protected]

91700717 ext. +47

Sponsors and collaborators

Lead sponsor

Oslo University Hospital

Other

Collaborators

  • Sensocure AS

Registry information

Official study title

Early Ischemia Detection by a Tissue CO2-sensor During Development of Acute Compartment Syndrome

Acronym: IDEA

Important dates

Study start
2025
Primary completion
2027
Study completion
2027
First posted
Oct 12, 2023
Registry last updated
Mar 25, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.